Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US

Medicare is the federal health insurance program for individuals in the US who are aged ≥65 years, select individuals with disabilities aged <65 years, and individuals with end-stage renal disease. The Centers for Medicare and Medicaid Services grants researchers access to Medicare administrative claims databases for epidemiologic and health outcomes research. The data cover beneficiaries’ encounters with the health care system and receipt of therapeutic interventions, including medications, procedures, and services. Medicare data have been used to describe patterns of morbidity and mortality, describe burden of disease, compare effectiveness of pharmacologic therapies, examine cost of care, evaluate the effects of provider practices on the delivery of care and patient outcomes, and explore the health impacts of important Medicare policy changes. Considering that the vast majority of US citizens ≥65 years of age have Medicare insurance, analyses of Medicare data are now essential for understanding the provision of health care among older individuals in the US and are critical for providing real-world evidence to guide decision makers. This review is designed to provide researchers with a summary of Medicare data, including the types of data that are captured, and how they may be used in epidemiologic and health outcomes research. We highlight strengths, limitations, and key considerations when designing a study using Medicare data. Additionally, we illustrate the potential impact that Centers for Medicare and Medicaid Services policy changes may have on data collection, coding, and ultimately on findings derived from the data.

[1]  David M. Diez,et al.  Comprehensive smoking bans and acute myocardial infarction among Medicare enrollees in 387 US counties: 1999-2008. , 2012, American journal of epidemiology.

[2]  T. Brown,et al.  Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: a cross-sectional study , 2014, BMC Health Services Research.

[3]  PeterChris Okpala,et al.  Medicare Prescription Drug, Improvement and Modernization Act , 2013 .

[4]  A. O'Malley,et al.  Interspecialty Communication Supported by Health Information Technology Associated with Lower Hospitalization Rates for Ambulatory Care–Sensitive Conditions , 2015, The Journal of the American Board of Family Medicine.

[5]  Michael J. Howley,et al.  Medicare Reimbursement for Total Joint Arthroplasty: The Driving Forces. , 2016, The Journal of bone and joint surgery. American volume.

[6]  P. Eggers,et al.  Effects of race and income on mortality and use of services among Medicare beneficiaries. , 1996, The New England journal of medicine.

[7]  E. Rackow Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[8]  W. John,et al.  Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients , 2017, Journal of medical economics.

[9]  L. Alecxih,et al.  Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries. , 1999, Health services research.

[10]  R. Rubin,et al.  Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  E. Klein,et al.  Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population , 2008, Cancer.

[12]  P. Muntner,et al.  Optimal use of available claims to identify a Medicare population free of coronary heart disease. , 2015, American journal of epidemiology.

[13]  A. J. O’Malley,et al.  Long-Term Outcomes of Abdominal Aortic Aneurysm in the Medicare Population. , 2015, The New England journal of medicine.

[14]  M Alan Brookhart,et al.  Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. , 2006, Arthritis and rheumatism.

[15]  A. Collins,et al.  Patient characteristics, disease burden, and medication use in stage 4 - 5 chronic kidney disease patients. , 2016, Clinical nephrology.

[16]  R. Platt,et al.  Impact of Policies on the Rise in Sepsis Incidence, 2000-2010. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[18]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[19]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[20]  R. Rubin,et al.  Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study , 2015, BMC Nephrology.

[21]  Mark S Levenson,et al.  Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. , 2016, JAMA internal medicine.

[22]  J. Wheeler,et al.  Provider monitoring and pay-for-performance when multiple providers affect outcomes: An application to renal dialysis. , 2009, Health services research.

[23]  T. Wilt,et al.  Reduction in physician reimbursement and use of hormone therapy in prostate cancer. , 2010, Journal of the National Cancer Institute.

[24]  Xianglin L. Du,et al.  Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer , 2014, PharmacoEconomics.

[25]  Michael K Adjemian,et al.  The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States. , 2015, Annals of the American Thoracic Society.

[26]  E John Orav,et al.  Readmissions, Observation, and the Hospital Readmissions Reduction Program. , 2016, The New England journal of medicine.

[27]  K. Rothman,et al.  Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. , 2016, Journal of the American Society of Nephrology : JASN.

[28]  A. Collins,et al.  Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis‐stimulating agent and transfusion use in chemotherapy‐treated cancer patients , 2012, Pharmacoepidemiology and drug safety.

[29]  C. O'connor,et al.  Fractures and mortality in relation to different osteoporosis treatments. , 2015, Clinical and experimental rheumatology.

[30]  T. Ikizler,et al.  Peer kidney care initiative 2014 report: dialysis care and outcomes in the United States. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  Hhs Centers for Medicare Medicare Services Medicare program; end-stage renal disease prospective payment system. Final rule. , 2010, Federal register.

[32]  Susan C. Miller,et al.  Changes in Medicare costs with the growth of hospice care in nursing homes. , 2015, The New England journal of medicine.

[33]  Thomas MaCurdy,et al.  Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. , 2015, The Lancet. Infectious diseases.

[34]  W. Kreuter,et al.  Specialty differences in polyp detection, removal, and biopsy during colonoscopy. , 2010, The American journal of medicine.

[35]  Charles E. Leonard,et al.  Validation of diagnostic codes for outpatient‐originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data , 2009, Pharmacoepidemiology and drug safety.

[36]  Jiayi Hou,et al.  The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer. , 2017, International journal of radiation oncology, biology, physics.